

# Contents

<b>Foreword</b>	<b>xxi</b>
<b>Preface</b>	<b>xxiii</b>
<b>CHAPTER 1</b>	
<b>The Statutory and Regulatory Scheme</b>	<b>1</b>
<hr/>	
I. The Drug Price Competition and Patent Term Restoration Act of 1984 (aka the Hatch-Waxman Act)	1
II. Statutory Overview and Specific Amendments	3
A. General Compromise	3
B. Legislative Foundation and Subsequent Amendments	5
III. Statutory Balancing: Incentives to Patentees and Generics	7
A. New Drug Application Filers	7
B. ANDA Filers	21
<b>CHAPTER 2</b>	
<b>The Drug Approval Process—An Overview</b>	<b>31</b>
<hr/>	
I. Pre-NDA Filing	32
II. NDA Filing and Post-NDA Filing	33
III. The FDA Process for Securing Drug Approval for a Drug under the ANDA Process	35
<b>CHAPTER 3</b>	
<b>Notice and Prefiling Considerations</b>	<b>39</b>
<hr/>	
I. The NDA Owner’s Pre–Notice Letter Investigation	39
A. Timeline for Receiving the Notice Letter	39
B. Presuit Due Diligence and Review of Orange Book Listings	41
II. Paragraph IV Notice Letters	48
A. Requirements	48
B. Estoppel and Reservation of Rights	49
C. Confidentiality	50
D. Considerations for the Notice Letter Recipient	51

III.	Considerations during the 45-Day Window	52
	A. Prefiling Investigation for NDA Holders	52
	B. The 30-Month Stay	54
	C. Protective Suits	55
	D. Joint Exclusivity	55
IV.	Declaratory-Judgment Actions	57
	A. Requirement 1: The 45-Day Review Period	60
	B. Requirement 2: No Suit on “the Patent”	60
	C. Requirement 3: Offer of Confidential Access to Application	60
V.	Confidential Access	61
	A. Contents of Offer	61
	B. Jurisdictional Prerequisite	61
	C. Obligations to Negotiate or Review ANDA	63
VI.	NDA Owner and Generic Tension regarding the 30-Month Stay	64
	A. The 30-Month Stay	64
	B. Modifying the 30-Month Stay	65
	C. Pediatric Exclusivity	67
	D. Considerations When Launching “At Risk”	68
VII.	The 180-Day Exclusivity Period	70
	A. Triggering Exclusivity under the Pre-MMA Framework	70
	B. Triggering Exclusivity under the Post-MMA Framework	72
	C. Obtaining Subject Matter Jurisdiction	73
VIII.	Non-Paragraph IV ANDA Litigation	74
 <b>CHAPTER 4</b>		
<b>The Litigation Timeline</b>		<b>77</b>
<hr/>		
I.	Introduction	77
II.	Logistics Following Receipt of the Notice Letter	77
	A. Selecting Counsel	77
	B. Choosing a Forum	78
III.	Scheduling the Case	83
	A. Impact of FDA Review	83
	B. ANDA-Specific Local Rules	85
	C. Bifurcation	88
	D. Contention Discovery	89
	E. Discovery	89
	F. Claim Construction	90
	G. Summary Judgment	91
	H. Trial	92
IV.	Post Trial and Appeals	93

<b>CHAPTER 5</b>	
<b>Hatch-Waxman Actions in Multidistrict Litigation</b>	<b>95</b>
I. The Electrical Equipment Antitrust Cases and the Beginning of Multidistrict Litigation	96
II. The United States Judicial Panel on Multidistrict Litigation	97
III. Transferring an Action for Consolidation	99
IV. Oral Argument of Motions to Consolidate	101
V. Panel Website	103
VI. Case Management/Electronic Case Files	103
VII. Filing Documents	104
VIII. Pro Se Litigants	106
IX. Tag-Along Actions and Conditional Transfer Orders	107
X. Termination and Remand of Multidistrict Litigation	108
XI. Self-Transfer	110
XII. <i>Lexecon</i> and the End of Self-Transfer	112
XIII. Brand Name Drug Manufacturers and the Omeprazole Litigation	113
XIV. Generic Manufacturers	115
XV. <i>TC Heartland</i> and the Effect on Multidistrict Litigation	116
XVI. ANDA MDL Statistics	117
<b>CHAPTER 6</b>	
<b>Biologics Litigation: The Biosimilars Wars</b>	<b>119</b>
I. Introduction	119
II. The Patent Dance	121
III. Market Information	123
IV. Case Summaries	126
A. Statutory Interpretation of the BPCIA	126
B. BPCIA Litigation	128
V. Biologics and Antitrust	154
A. Remicade (infliximab) Antitrust Litigation	155
B. Humira (adalimumab) Antitrust Litigation	156
<b>CHAPTER 7</b>	
<b>Initiating Litigation</b>	<b>159</b>
I. Parties	159
A. Proper Plaintiffs	159
B. Proper Defendants	160
II. Venue and Personal Jurisdiction	162
A. Personal Jurisdiction	162
B. Venue	163

III. Infringement	168
A. 35 U.S.C. § 271(e)	168
B. Differences from Ordinary Patent Infringement	170
IV. Juries and the Hatch-Waxman Act	174
A. No Right to a Jury for § 271(e)(2) Claims	174
B. No Right to a Jury for Counterclaims to § 271(e)(2) Claims	174
C. Availability of Damages Remedy Impacts Right to a Jury	176

## **CHAPTER 8**

### **Use of Reissue Proceedings in Hatch-Waxman Litigation** **179**

---

I. Introduction	179
II. The Reissue Application	179
A. What Can Be Corrected in a Reissue Application	180
B. What Cannot Be Corrected in a Reissue Application	182
III. Risks of Reissue	185
IV. The Use of Reissue Applications after Litigation	187
A. Celebrex	188
B. Teva Crafts from Celecoxib a Strategy to Save Copaxone	190
V. Conclusion	192

## **CHAPTER 9**

### **Inter Partes Review in ANDA Litigation** **193**

---

I. Introduction to the AIA and Inter Partes Review	193
II. Procedure	195
A. Filing an IPR Petition	195
B. Responding to the Petition	197
C. Institution	198
D. Post Institution/Trial	201
E. Appeal	204
III. Interplay between Hatch-Waxman and Inter Partes Review	204
A. Motions to Stay/Effect on 30-Month Stay	206
B. Market Exclusivity	207
C. Conflicts of Decisions	208
D. Estoppel	209
IV. Filing and Defending IPRs	209
A. Offensive IPR Strategies and Considerations	209
B. Defensive IPR Strategies and Considerations	211
V. Conclusion	213

<b>CHAPTER 10</b>	
<b>Examining Subject-Matter Jurisdiction over Declaratory Judgment Claims Filed in Combination with Patent Infringement Claims under Section 271(e)(2)(A)</b>	<b>215</b>
<hr/>	
I. Introduction	215
II. Background on Subject-Matter Jurisdiction over Declaratory Judgment Claims	216
III. Analysis of Pertinent Decisions, 2015–2019	217
A. <i>Noven</i> (District of New Jersey, 2015)	218
B. <i>United Therapeutics</i> (District of New Jersey, 2015)	219
C. <i>Takeda</i> (District of Delaware, 2017)	220
D. <i>Allergan</i> (Eastern District of Texas, 2017)	222
E. <i>Celgene</i> (District of New Jersey, 2018)	222
F. <i>Ferring</i> (District of Delaware, 2018)	223
G. <i>Vanda</i> (Federal Circuit, 2018)	225
IV. Trends in Application of Declaratory Judgment Jurisdiction in ANDA Cases	227
A. Paragraph IV Certification Not a Prerequisite for a Section 271(e)(2)(A) Claim	227
B. Facts Favoring the Exercise of Subject-Matter Jurisdiction over Declaratory Judgment Claims	227
C. Factors Favoring a Lack of Subject-Matter Jurisdiction	228
<b>CHAPTER 11</b>	
<b>Responding to the Complaint</b>	<b>231</b>
<hr/>	
I. Introduction to Responses in the Hatch-Waxman Litigation Context	231
II. Pre-answer Motions	231
A. Motions to Dismiss	231
B. Motion for Sanctions under Rule 11	256
III. The Answer	257
A. Defenses	257
B. Additional Counterclaims	268
IV. Nonlitigation Alternatives	271
<b>CHAPTER 12</b>	
<b>Discovery</b>	<b>273</b>
<hr/>	
I. Introduction	273
II. Paragraph IV Certification and the Notice Letter	274
A. Initiation of ANDA Litigation and the ANDA Notice Letter	274
B. Discovery Related to the Paragraph IV Certification and Notice Letter	275

III. Federal Rules of Civil Procedure 26(f), Initial Scheduling Conference	276
A. Initial Disclosures Pursuant to Rule 26	277
B. Asserted Claims, Infringement Contentions, and Invalidity Contentions	277
C. Scope and Timing of Claim Construction	278
D. Fact Discovery and Expert Discovery Periods	279
E. Filing Papers under Seal	280
F. Motions for Summary Judgment	280
G. Pretrial Conference and Trial	280
IV. The Protective Order	281
A. Confidentiality Tiers	281
B. Data Privacy and Foreign Data Protection Laws	282
C. Provisions for the Production of Discovery and ESI	282
D. Inadvertent Failure to Designate or Production of Privileged Materials	283
E. Use of ANDA Discovery Outside of ANDA Litigation	283
V. Fact Discovery	283
A. Infringement and Invalidity Contentions	284
B. Discovery Requests: Requests for Production, Interrogatories, and Requests for Admission	285
C. Fact Depositions	285
VI. Expert Discovery	287
VII. Extension of Discovery and the 30-Month Stay	287

## CHAPTER 13

### Experts

**289**

I. Introduction	289
A. Selection of Experts in ANDA Cases	290
B. Timing	291
II. Expert Involvement during Pretrial Proceedings	292
A. Expert Involvement in Directing Discovery	292
B. The Expert Report—Legal and Factual Framework	293
C. Expert Testing or Analysis	303
D. Discovery of the Expert's Documents and Things	306
E. The Expert Deposition	306
F. Trial Preparation of the Expert	307
III. Expert Involvement in Trial	308
A. Qualifications of the Expert	308
B. Expert Use of Demonstratives	312
C. Sources and Evidence on Which the Expert May Rely	314

<b>CHAPTER 14</b>	
<b>Claim Construction</b>	<b>315</b>
<hr/>	
I. General Aspects of Claim Construction	315
A. Claim Construction Principles	316
B. Claim Construction Procedure and Timing Issues	326
II. Claim Construction Specific to ANDA Cases	330
A. Strategic Considerations	330
B. Sources of Evidence	331
C. Claim Construction Issues and Examples	332
III. The Claim Construction Hearing	340
A. Preparing to Argue the Merits	340
B. The Technology Tutorial	340
C. The Claim Construction Presentation and Demonstratives	341
IV. Appealing and Revisiting Claim Construction	341
<b>CHAPTER 15</b>	
<b>Summary Judgment</b>	<b>343</b>
<hr/>	
I. The Ideal Adjudication for a Hatch-Waxman Case	344
A. Objectives of the Hatch-Waxman Act Include Early Resolution of Patent Issues	344
B. A Summary Judgment Motion Can Expedite the Adjudication of a Hatch-Waxman Case	347
C. The Judge, as Fact-Finder in a Nonjury Case, Has More Flexibility in Resolving the Ultimate Dispute	349
D. Uncertainty of the Final Approved ANDA Product Is a Factor in Seeking a Summary Judgment for Noninfringement	350
II. Rule 56 and General Legal Principles Relating to Summary Judgment	352
A. A Brief History of Rule 56 and the 1986 Trilogy of Summary Judgment Decisions by the U.S. Supreme Court	352
B. Principles of Rule 56, Including the 2010 Amendments	353
III. Factors and Strategies to Consider in Filing a Summary Judgment Motion in a Hatch-Waxman Case	360
A. Timing as a Strategy	360
B. Summary Judgment as a Means for Obtaining an Adversary's Positions	362
C. The Interplay of a Summary Judgment Motion and Patent Claim Construction Proceedings	363

D. A Summary Judgment Motion Can Encourage Settlement Discussions	364
E. Court Presiding over Case as a Consideration	367
IV. The Summary Judgment Motion Seeking Adjudication of the Infringement Issue	370
A. General Legal Principles Applicable to Deciding Patent Infringement on Summary Judgment	370
B. Summary Judgment for Noninfringement Is Frequently Sought by ANDA Applicants	373
C. The Status of the ANDA Product Is an Important Factor in Determining Infringement on Summary Judgment	376
D. Issues of Fact Frequently Raised by Patentee to Defeat Summary Judgment of Noninfringement	383
V. Motions for Summary Judgment on Patent Validity Issues	383
VI. Motions for Summary Judgment Relating to Patent Enforceability	386
VII. Reconsideration or Appeal of a Summary Judgment Decision	388

## CHAPTER 16

### Remedies

**391**

I. Introduction	391
II. Section 271(e)(4)(A)—FDA Preclusion Orders	392
A. ANDA Approval Date	392
B. Approved and Unapproved ANDAs	393
C. Post-Patent Expiration Remedy	395
III. Section 271(e)(4)(B)—Injunctions	396
A. Temporary Injunctive Relief	397
B. Permanent Injunctive Relief	415
C. Equitable Defenses	419
D. Scope and Parties Bound	420
E. Enforcing the Injunction Order	421
IV. Section 271(e)(4)(C)—Money Damages	425
A. Monetary Damages Are Unavailable before Launch	425
B. “Damages and Other Monetary Relief” Are Available under Section 271 for an At-Risk Launch	426
C. Attorneys’ Fees under Section 285 Are Available	428
D. Willfulness Damages under Section 284 Are Not Available	429
E. Mandatory Reasonable Royalties under Section 271(e)(6) Are Available for Certain Biologicals	430



<b>CHAPTER 17</b>	
<b>Settlement</b>	<b>431</b>
<hr/>	
I. Introduction	431
II. Frequency of Settlement	431
III. Types of Settlement Agreements	432
A. Compensation to Generics	433
B. Authorized Generics	437
C. Licenses to Products and Technologies outside the Scope of the Litigation	438
D. Co-Promotion and Profit-Sharing	439
E. Joint Venture Agreements	440
IV. Checklist: Considerations and Items to Include in a Settlement Agreement	440
A. Common Interest/Joint Defense Agreements	440
B. Avoiding Antitrust Violations	441
C. No-Challenge Provisions	442
D. Releases for Past and Future Infringement	443
E. Most Favored Nation Clauses	443
F. Ability to Transfer ANDA	444
G. Attorneys' Fees	444
H. Stockpiling of Generic Drugs	444
V. Disclosure of Settlement Agreements	445
A. Types of Agreements That Must Be Filed	445
B. Filing Requirements	446
C. Enforcement Procedures	447
<b>CHAPTER 18</b>	
<b>Antitrust</b>	<b>449</b>
<hr/>	
I. Overview of Antitrust Issues	449
II. Legal Theories in ANDA Antitrust Cases	450
A. Pay-for-Delay/Conspiracy (Sherman Act, Section 1) Offenses	451
B. Monetary Agreements	452
C. Non-Monetary Agreements	453
D. Separate Agreements	456
E. Potential Plaintiffs	457
F. States	463
G. Unilateral Conduct/Monopolization (Sherman Act, Section 2) Offenses	464
H. Other Sherman Act Section 1 Offenses	472
I. State Law Claims	473

III. Remedies	473
A. Money Damages for Antitrust Violation	473
B. Attorneys' Fees Awarded to Generic for Exceptional Case	474
C. Disgorgement	475
D. Injunctive Relief	476
<b>CHAPTER 19</b>	
<b>Pretrial Preparation</b>	<b>479</b>
<hr/>	
I. Trial Plan and Themes	479
A. Narrowing the Issues	479
B. Burdens of Proof	480
C. Refining Case Themes	482
D. Planning the Trial Presentation	484
E. Opening Statements and Closing Arguments	485
II. Selection and Preparation of Witnesses	485
A. Fact Witnesses	486
B. Expert Witnesses	486
III. Exhibits and Demonstratives	487
IV. Trial Consultants and Mock Trials	488
V. Notice Pursuant to Section 282	489
VI. Pretrial Orders and Statements	489
A. Pretrial Orders	489
B. Proposed Findings of Fact	491
C. 30-Month Stay	492
D. Local Rules	492
VII. <i>Daubert</i> Motions	492
VIII. Motions in Limine	496
A. Deciding Which Motions to File	496
B. Motions Common to ANDA Cases	496
IX. Pretrial Conferences	498
A. Scheduling	498
B. Trial Conduct	499
C. Order of Proofs and Bifurcation	499
X. Logistical Preparations	499
<b>CHAPTER 20</b>	
<b>Trial</b>	<b>501</b>
<hr/>	
I. Introduction	501
II. Pretrial	502
A. Pretrial Order	502
B. Pretrial Conference and Start of Trial	503
III. Opening Statements	504

IV. Witness Preparation	505
A. Preparing for Direct Examination	506
B. Preparing for Cross-Examination	507
C. Other Preparation Considerations	508
V. The Witness Disclosure and Witness Exhibit Dance	509
VI. Direct Examination	510
A. Live Witnesses	510
B. Testimony by Deposition	517
C. Using Demonstratives	518
D. Rhetorical Techniques	519
E. Getting Exhibits Admitted into Evidence	520
F. Objections to the Opposing Parties' Exhibits and Evidence	521
G. Tendering Witness for Cross-Examination	521
VII. Cross-Examination	522
VIII. Special Considerations in Multidefendant Trials	526
A. For Defendants	526
B. For Plaintiffs	527
IX. Rule 52 Motions	528
X. Closing Arguments and Post-trial Submissions	530
A. Logistics of the Closing	530
B. Preparation and Strategy for Closing	531
C. General Approach to Post-trial Submissions	532
XI. Being Effective at Trial as an Inexperienced Attorney	533
A. The Effective Second Chair Attorney	534
B. The Effective Trial Runner	535
C. A Final Word on Effort and Attitude	536
<b>CHAPTER 21</b>	
<b>Post-trial</b>	<b>537</b>
I. Post-trial Considerations	537
II. Bench Rulings after the Close of Evidence	537
III. Post-trial Briefing, Proposed Findings of Fact, and Conclusions of Law	539
IV. Motions for a Preliminary Injunction If No Decision Issues before the Expiration of the Automatic Stay	541
V. Other Post-trial Applications	543
A. Stay Pending Appeal by Brand	543
B. Permanent Injunction	544
C. Supplementing the Record	545
VI. Procedural Alternatives before Appeal	546

<b>CHAPTER 22</b>	
<b>Appeals to the Court of Appeals for the Federal Circuit</b>	<b>549</b>
<hr/>	
I. Scope of Review	551
II. Mechanics of Filing the Appeal	554
III. Preparing the Shell	563
A. Introduction	563
B. Statement of Related Cases	564
C. Jurisdictional Statement	564
D. Statement of the Issues	564
E. Statement of the Case: Setting Out the Facts Relevant to the Issues	565
F. Summary of the Argument	566
G. Argument	567
IV. Answering Brief	567
V. Drafting Federal Circuit Appeal Briefs	568
VI. Oral Argument	570
<b>CHAPTER 23</b>	
<b>Hatch-Waxman Practice in the Supreme Court of the United States</b>	<b>575</b>
<hr/>	
I. <i>Eli Lilly &amp; Co. v. Medtronic, Inc.</i> (1990)	576
II. <i>Merck KGaA v. Integra Lifesciences I, Ltd.</i> (2005)	577
III. <i>PLIVA, Inc. v. Mensing</i> (2011)	578
IV. <i>Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S</i> (2012)	580
V. <i>Federal Trade Commission v. Actavis, Inc.</i> (2013)	584
VI. <i>Mutual Pharmaceutical Co. v. Bartlett</i> (2013)	587
VII. <i>Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.</i> (2015)	588
VIII. <i>TC Heartland LLC v. Kraft Foods Group Brands, LLC</i> (2017)	590
IX. <i>Sandoz Inc. v. Amgen Inc.</i> (2017)	591
X. <i>Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.</i> (2019)	594
XI. Conclusion	596
<b>CHAPTER 24</b>	
<b>Managing an ANDA Litigation</b>	<b>599</b>
<hr/>	
I. Introduction	599
II. Initial Considerations	600
A. Assessing the Client's Business Needs	600
B. Assembling a Litigation Team	602
C. Experts and Consultants	603
D. Budget	604

III. Progression of the ANDA Litigation	606
A. Preliminary Logistics	606
B. Discovery	607
C. Narrowing the Issues for Trial	613
D. Trial Organization	614
IV. Conclusion	615

## CHAPTER 25

### Pharmaceutical Regulation and Litigation in Foreign Countries 617

I. Australia	617
A. The Statutory and Regulatory Scheme	617
B. Notice, Prefiling Requirements, and Patent Linkage Rules	629
C. The Litigation Process	633
D. Remedies	637
E. Strategic Recommendations	638
II. Brazil	639
A. Introduction	639
B. Patent Portfolio	639
C. Clinical Trials	641
D. Regulatory Submission of Drug Application	642
E. Strategies	647
F. Extrajudicial Measures	648
G. Possible Patent Term Extension for a Pharmaceutical Product	649
H. Partnership for Productive Development	649
III. Canada	651
A. Introduction	651
B. Overview of the Statutory and Regulatory Scheme for Pharmaceuticals	652
C. The PM(NOC) Regulations	657
D. Strategic Considerations	670
IV. European Union and United Kingdom	671
A. The Statutory and Regulatory Scheme	671
B. Outline of the EU Regulatory Legal Framework	676
C. Procedures for the Grant of a Marketing Authorization	678
D. Requirements for a Full Application for MA and the Right to Regulatory Data Protection	681
E. Requirements for Abridged Applications for an MA	685
F. Other Legal Bases for an Application for MA	688
G. The Regulatory Regime Relating to Orphan Medicinal Products	690
H. Strategies and Hurdles in the Enforcement of IP Regulatory Rights	693

I. The Interface between Regulatory IP Rights and Patent Protection	705
J. Conclusion	709
<b>APPENDIX</b>	<b>711</b>
<hr/>	
<b>INDEX</b>	<b>963</b>
<hr/>	